World Health Organization Issues Alert Over Acute Shortage of Weight-Loss Medications

Under 10% of people who could benefit from obesity jabs including Wegovy can access them, warns the WHO as it releases its initial recommendations on the drugs.

Given in excess of 1,000,000,000 people worldwide currently obese, it is advocating for increased and just access to this class of drugs.

According to estimates, more than two billion are projected to be living with obesity by 2030 if no action is taken.

"Our new guidelines acknowledges that excess weight is a lifelong illness that can be managed with thorough and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and supply-chain constraints are major barriers to widespread access to the treatments that can assist patients in reducing considerable weight, explains the body.

Skinny Jab Scarcity

Even under the present most favorable scenario, the supply of GLP-1 therapies would only suffice for approximately 100 million people – fewer than 10% of eligible patients, per the WHO.

The guideline calls on nations and manufacturers to widen access, via approaches such as licensing agreements.

Exclusive production rights on a key compound – the primary ingredient of a leading brand – is set to lapse in a number of nations in 2026.

How Weight-Loss Drugs Operate

The injections imitate a biological compound to slow digestion, suppress the appetite and boost the sense of being full so users consume fewer calories.

People typically begin shedding pounds in the initial weeks of beginning the regular doses.

Research suggests patients may regain a significant portion a year later of discontinuing the medication, because their typical hunger resume.

To be above a healthy weight raises your chance for contracting medical conditions, including diabetes, heart disease, stroke, and some cancers.

Excess weight impacts people in all nations and was responsible for 3.7 million deaths worldwide in 2024, per the WHO.